|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis.
|
30909793 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pediatric anaplastic large-cell lymphoma (ALCL), which is characterized by strong expression of CD30, is usually responsive to multidrug chemotherapy.
|
31274669 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma.
|
31476851 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.
|
31002934 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significance of raising physician awareness regarding pediatric oral EBV associated CD30 positive lymphoproliferative disease of the oral cavity lies in preventing inadvertent exposure to toxic chemotherapeutic agents intended for treatment of aggressive look-alikes, namely anaplastic large cell lymphoma.
|
30292067 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis.
|
29617304 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
|
29597249 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concentrations of interleukin-9, interleukin-10, interleukin-17a, hepatocyte growth factor, soluble interleukin-2 receptor, and soluble CD30 were significantly higher in initial sera of patients than in the sera of subjects from both control groups, indicating an anaplastic large cell lymphoma-type cytokine signature.
|
29242300 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 was assessed frequently but not uniformly in cases that were not anaplastic large cell lymphoma.
|
28209473 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As expected, strong and membranous CD30 staining was seen in anaplastic large cell lymphoma, classical Hodgkin lymphoma, and embryonal carcinoma while variable staining was seen in diffuse large B cell lymphoma.
|
28521633 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin.
|
28805086 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sinusoidal CD30+ diffuse large B-cell lymphoma can masquerade as anaplastic large cell lymphoma in pediatric posttransplant lymphoproliferative disorders.
|
28035754 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas.
|
27521276 |
2016 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
|
25145835 |
2014 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.
|
24404580 |
2013 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-three of 487 pediatric patients registered within the Anaplastic Large Cell Lymphoma-99 trial (1999 to 2006) presented with a skin limited CD30-positive lympho-proliferative disorder.
|
22773605 |
2013 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 is highly expressed on Hodgkins lymphoma and anaplastic large cell lymphoma, making it an attractive target for therapy.
|
23968853 |
2013 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
|
22107829 |
2012 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
They include lymphomatoid papulosis and cutaneous anaplastic large-cell lymphoma which are characterized by the common expression of the CD30 antigen, but different clinical, histological and molecular features.
|
23149700 |
2012 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed combined CDKN2A-CDKN2B deletion in both transformed mycosis fungoides (n=17, 71%) and SS patients (n=7, 44%), but, surprisingly, in only one CD30+ cutaneous anaplastic large cell lymphoma case.
|
20118908 |
2010 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.
|
19890350 |
2010 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma.
|
17973241 |
2008 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
|
17320171 |
2008 |